Pharmaceuticals News and Research

RSS

NSU-COM to hold grand opening for America's first Institute for Neuro Immune Medicine

Nova Southeastern University's College of Osteopathic Medicine (NSU-COM) will hold a grand opening for America's first Institute for Neuro Immune Medicine on Feb. 12.

5 Feb 2013

State roundup: Minn. officials want money for coverage expansion

Gov. Mark Dayton and his Human Services commissioner will travel to Washington, D.C., this week to lobby for federal money for MinnesotaCare. MinnesotaCare is a state-subsidized health plan that insures about 130,000 people under age 65. Dayton and Commissioner Lucinda Jesson are scheduled to meet Tuesday in Washington with Health and Human Services Secretary Kathleen Sebelius.

5 Feb 2013

MSF claims aid for vaccines subsidizing pharmaceutical companies, Guardian reports

"Large sums of public money intended to ensure children in the developing world are immunized against disease are effectively being used to subsidize Big Pharma, doctors working in the field claim," the Guardian reports.

5 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

Maimonides, Navidea to evaluate Lymphoseek use in lymphatic mapping for colorectal cancer

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it has entered into an agreement to collaborate with Maimonides Medical Center to investigate the utility of Lymphoseek (technetium Tc 99m tilmanocept) Injection in lymphatic mapping procedures for colorectal cancer.

5 Feb 2013

USPTO issues patent to KAHR-101 for treatment of cancers, arthritis and MS

Hadasit Bio-Holdings Ltd., a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, KAHR Medical Ltd., was granted a U.S. patent approval (U.S. Patent No. 8329657).

5 Feb 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

Sun Pharma receives FDA approval for generic Doxil

The U.S. Food and Drug Administration today approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection).

4 Feb 2013

Viewpoints: Obama's 'olive branch' on birth control coverage; Sen. Kirk recounts his stroke therapy; Nurses oppose mandatory flu shots

The Obama administration released the final details Friday of the exemption it will provide religious-affiliated employers from the requirement to include free birth control in employees' insurance policies. Not surprisingly, the announcement didn't seem to mollify any of the critics who'd been arguing that the exemption was inadequate.

4 Feb 2013

Scientists receive honorary doctorate for research on Alzheimer's disease

On Monday 4 February, Dennis J. Selkoe and five other "brain teasers" will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate - VIB-KU Leuven professors Bart De Strooper and Wim Robberecht - will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer's Disease and other conditions that cause severe damage in the brain.

4 Feb 2013

Science reports on reform in China's health care system

Science examines reforms taking place within the Chinese health care system, which "aim to expand infrastructure, cover the poor, and combat chronic diseases," according to the journal.

3 Feb 2013

Potential connection between autism and insulin-like growth factor

A New York-based physician-researcher from Touro College of Osteopathic Medicine, best known for his research into fertility and twinning, has uncovered a potential connection between autism and a specific growth protein that could eventually be used as a way to predict an infant's propensity to later develop the disease.

2 Feb 2013

Viewpoints: Health law's 'implausible' foundations; 4 needed health reforms; Sunlight on drugmaker payments to doctors

As the federal government moves forward to implement President Obama's Affordable Care Act, the Department of Health and Human Services is slated to spend millions of dollars promoting the unpopular legislation. In the face of this publicity blitz, it is worth remembering that the law was originally sold largely on four grounds - all of which have become increasingly implausible.

2 Feb 2013

Pharmacuetical companies eye orphan drugs as new revenue source

Drug companies are fond of saying that every patient counts, but in the world of orphan diseases, entire business plans are built around the idea. ... Development of these drugs is increasingly attractive to pharmaceutical companies, which are searching for new sources of revenue as sales of more traditional, mass-market drugs have been lost to generic competition.

1 Feb 2013

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

UC Irvine biologists, chemists and computer scientists have identified an elusive pocket on the surface of the p53 protein that can be targeted by cancer-fighting drugs. The finding heralds a new treatment approach, as mutant forms of this protein are implicated in nearly 40 percent of diagnosed cases of cancer, which kills more than half a million Americans each year.

1 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

Vanda Pharmaceuticals Inc. today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD.

31 Jan 2013

DelMar announces second closing of $1.5M in private placement

DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.

31 Jan 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Pharmaceuticals News and Research

NSU-COM to hold grand opening for America's first Institute for Neuro Immune Medicine

State roundup: Minn. officials want money for coverage expansion

MSF claims aid for vaccines subsidizing pharmaceutical companies, Guardian reports

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

Maimonides, Navidea to evaluate Lymphoseek use in lymphatic mapping for colorectal cancer

USPTO issues patent to KAHR-101 for treatment of cancers, arthritis and MS

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Sun Pharma receives FDA approval for generic Doxil

Viewpoints: Obama's 'olive branch' on birth control coverage; Sen. Kirk recounts his stroke therapy; Nurses oppose mandatory flu shots

Scientists receive honorary doctorate for research on Alzheimer's disease

Science reports on reform in China's health care system

Potential connection between autism and insulin-like growth factor

Viewpoints: Health law's 'implausible' foundations; 4 needed health reforms; Sunlight on drugmaker payments to doctors

Pharmacuetical companies eye orphan drugs as new revenue source

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

DelMar announces second closing of $1.5M in private placement

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence